

SAFETY DATA SHEET



MVP Total RNA - Human HeLa S3 Cells with and without PMA treatment, Part Number 540113

Section 1. Identification

1.1 Product identifier

Product name : MVP Total RNA - Human HeLa S3 Cells with and without PMA treatment, Part Number 540113

Part No. (Chemical Kit) : 540113

Part No. : MVP Total RNA, Human HeLa S3 Cells 540087-41
 MVP Total RNA, Human HeLa S3 Cells, PMA-treated 540097-41

Validation date : 2015-09-01

1.2 Relevant identified uses of the substance or mixture and uses advised against

Material uses : Analytical reagent.

MVP Total RNA, Human HeLa S3 Cells 0.025 ml
 MVP Total RNA, Human HeLa S3 Cells, PMA-treated 0.028 ml

1.3 Details of the supplier of the safety data sheet

Supplier/Manufacturer : Agilent Technologies, Inc.
 5301 Stevens Creek Blvd
 Santa Clara, CA 95051, USA
 800-227-9770

1.4 Emergency telephone number

In case of emergency : CHEMTREC®: 1-800-424-9300

Section 2. Hazards identification

2.1 Classification of the substance or mixture

OSHA/HCS status : MVP Total RNA, Human HeLa S3 Cells	While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated	While this material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200), this SDS contains valuable information critical to the safe handling and proper use of the product. This SDS should be retained and available for employees and other users of this product.

Classification of the substance or mixture

Not classified.

2.2 GHS label elements

Signal word : MVP Total RNA, Human HeLa S3 Cells No signal word.
 MVP Total RNA, Human HeLa S3 Cells, PMA-treated No signal word.

Section 2. Hazards identification

Hazard statements	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.

Precautionary statements

Prevention	: MVP Total RNA, Human HeLa S3 Cells	Not applicable.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not applicable.

Response	: MVP Total RNA, Human HeLa S3 Cells	Not applicable.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not applicable.

Storage	: MVP Total RNA, Human HeLa S3 Cells	Not applicable.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not applicable.

Disposal	: MVP Total RNA, Human HeLa S3 Cells	Not applicable.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not applicable.

Supplemental label elements	: MVP Total RNA, Human HeLa S3 Cells	None known.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	None known.

2.3 Other hazards

Hazards not otherwise classified	: MVP Total RNA, Human HeLa S3 Cells	None known.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	None known.

Section 3. Composition/information on ingredients

Substance/mixture	: MVP Total RNA, Human HeLa S3 Cells	Mixture
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Mixture

Any concentration shown as a range is to protect confidentiality or is due to batch variation.

There are no ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment and hence require reporting in this section.

Occupational exposure limits, if available, are listed in Section 8.

Section 4. First aid measures

4.1 Description of necessary first aid measures

Eye contact	: MVP Total RNA, Human HeLa S3 Cells	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Get medical attention if irritation occurs.

Section 4. First aid measures

Inhalation	: MVP Total RNA, Human HeLa S3 Cells	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Remove victim to fresh air and keep at rest in a position comfortable for breathing. Get medical attention if symptoms occur.
Skin contact	: MVP Total RNA, Human HeLa S3 Cells	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Flush contaminated skin with plenty of water. Remove contaminated clothing and shoes. Get medical attention if symptoms occur.
Ingestion	: MVP Total RNA, Human HeLa S3 Cells	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Wash out mouth with water. Remove victim to fresh air and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Do not induce vomiting unless directed to do so by medical personnel. Get medical attention if symptoms occur.

4.2 Most important symptoms/effects, acute and delayed

Potential acute health effects

Eye contact	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Inhalation	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Skin contact	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Ingestion	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.

Over-exposure signs/symptoms

Eye contact	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.
Inhalation	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.

Section 4. First aid measures

Skin contact	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.
Ingestion	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.

4.3 Indication of immediate medical attention and special treatment needed, if necessary

Notes to physician	: MVP Total RNA, Human HeLa S3 Cells	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.
Specific treatments	: MVP Total RNA, Human HeLa S3 Cells	No specific treatment.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific treatment.
Protection of first-aiders	: MVP Total RNA, Human HeLa S3 Cells	No action shall be taken involving any personal risk or without suitable training.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No action shall be taken involving any personal risk or without suitable training.

See toxicological information (Section 11)

Section 5. Fire-fighting measures

5.1 Extinguishing media

Suitable extinguishing media	: MVP Total RNA, Human HeLa S3 Cells	Use an extinguishing agent suitable for the surrounding fire.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Use an extinguishing agent suitable for the surrounding fire.
Unsuitable extinguishing media	: MVP Total RNA, Human HeLa S3 Cells	None known.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards arising from the chemical	: MVP Total RNA, Human HeLa S3 Cells	In a fire or if heated, a pressure increase will occur and the container may burst.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	In a fire or if heated, a pressure increase will occur and the container may burst.
Hazardous thermal decomposition products	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.

5.3 Advice for firefighters

Section 5. Fire-fighting measures

Special protective actions for fire-fighters	: MVP Total RNA, Human HeLa S3 Cells	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training.
Special protective equipment for fire-fighters	: MVP Total RNA, Human HeLa S3 Cells	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode.

Section 6. Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

For non-emergency personnel	: MVP Total RNA, Human HeLa S3 Cells	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Put on appropriate personal protective equipment.
For emergency responders	: MVP Total RNA, Human HeLa S3 Cells	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".

6.2 Environmental precautions

: MVP Total RNA, Human HeLa S3 Cells	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).
MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air).

6.3 Methods and materials for containment and cleaning up

Section 6. Accidental release measures

Methods for cleaning up	: MVP Total RNA, Human HeLa S3 Cells	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Stop leak if without risk. Move containers from spill area. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.

Section 7. Handling and storage

7.1 Precautions for safe handling

Protective measures	: MVP Total RNA, Human HeLa S3 Cells	Put on appropriate personal protective equipment (see Section 8).
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Put on appropriate personal protective equipment (see Section 8).
Advice on general occupational hygiene	: MVP Total RNA, Human HeLa S3 Cells	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.
	MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.

7.2 Conditions for safe storage, including any incompatibilities

: MVP Total RNA, Human HeLa S3 Cells	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Store in accordance with local regulations. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination.

7.3 Specific end use(s)

Section 7. Handling and storage

- Recommendations** : MVP Total RNA, Human HeLa S3 Cells Industrial applications, Professional applications.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated Industrial applications, Professional applications.
- Industrial sector specific solutions** : MVP Total RNA, Human HeLa S3 Cells Not applicable.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated Not applicable.

Section 8. Exposure controls/personal protection

8.1 Control parameters

Occupational exposure limits

Ingredient name	Exposure limits
None.	

8.2 Exposure controls

Appropriate engineering controls : Good general ventilation should be sufficient to control worker exposure to airborne contaminants.

Environmental exposure controls : Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

Individual protection measures

Hygiene measures : Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working period. Appropriate techniques should be used to remove potentially contaminated clothing. Wash contaminated clothing before reusing. Ensure that eyewash stations and safety showers are close to the workstation location.

Eye/face protection : Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: safety glasses with side-shields.

Skin protection

Hand protection : Chemical-resistant, impervious gloves complying with an approved standard should be worn at all times when handling chemical products if a risk assessment indicates this is necessary.

Body protection : Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Other skin protection : Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.

Respiratory protection : Use a properly fitted, air-purifying or air-fed respirator complying with an approved standard if a risk assessment indicates this is necessary. Respirator selection must be based on known or anticipated exposure levels, the hazards of the product and the safe working limits of the selected respirator.

Section 9. Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance

Physical state	: MVP Total RNA, Human HeLa S3 Cells	Liquid.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Liquid.
Color	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Odor	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Odor threshold	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
pH	: MVP Total RNA, Human HeLa S3 Cells	8
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	8
Melting point	: MVP Total RNA, Human HeLa S3 Cells	0°C (32°F)
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	0°C (32°F)
Boiling point	: MVP Total RNA, Human HeLa S3 Cells	100°C (212°F)
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	100°C (212°F)
Flash point	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Evaporation rate	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Flammability (solid, gas)	: MVP Total RNA, Human HeLa S3 Cells	Not applicable.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not applicable.
Lower and upper explosive (flammable) limits	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Vapor pressure	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.
Vapor density	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.

Section 9. Physical and chemical properties

Relative density	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available. Not available.
Solubility	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Easily soluble in the following materials: cold water and hot water. Easily soluble in the following materials: cold water and hot water.
Partition coefficient: n-octanol/water	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available. Not available.
Auto-ignition temperature	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available. Not available.
Decomposition temperature	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available. Not available.
Viscosity	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available. Not available.

Section 10. Stability and reactivity

10.1 Reactivity	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific test data related to reactivity available for this product or its ingredients. No specific test data related to reactivity available for this product or its ingredients.
10.2 Chemical stability	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	The product is stable. The product is stable.
10.3 Possibility of hazardous reactions	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Under normal conditions of storage and use, hazardous reactions will not occur. Under normal conditions of storage and use, hazardous reactions will not occur.
10.4 Conditions to avoid	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data. No specific data.
10.5 Incompatible materials	: MVP Total RNA, Human HeLa S3 Cells MVP Total RNA, Human HeLa S3 Cells, PMA-treated	May react or be incompatible with oxidizing materials. May react or be incompatible with oxidizing materials.

Section 10. Stability and reactivity

10.6 Hazardous decomposition products	: MVP Total RNA, Human HeLa S3 Cells	Under normal conditions of storage and use, hazardous decomposition products should not be produced.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Under normal conditions of storage and use, hazardous decomposition products should not be produced.

Section 11. Toxicological information

11.1 Information on toxicological effects

Acute toxicity

Not available.

Irritation/Corrosion

Not available.

Sensitization

Not available.

Mutagenicity

Not available.

Carcinogenicity

Not available.

Reproductive toxicity

Not available.

Teratogenicity

Not available.

Specific target organ toxicity (single exposure)

Not available.

Specific target organ toxicity (repeated exposure)

Not available.

Aspiration hazard

Not available.

Information on the likely routes of exposure	: MVP Total RNA, Human HeLa S3 Cells	Not available.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	Not available.

Potential acute health effects

Eye contact	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Inhalation	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Skin contact	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.

Section 11. Toxicological information

Ingestion	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.

Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.
Inhalation	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.
Skin contact	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.
Ingestion	: MVP Total RNA, Human HeLa S3 Cells	No specific data.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No specific data.

Delayed and immediate effects and also chronic effects from short and long term exposure

Short term exposure

Potential immediate effects	: Not available.
Potential delayed effects	: Not available.

Long term exposure

Potential immediate effects	: Not available.
Potential delayed effects	: Not available.

Potential chronic health effects

General	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Carcinogenicity	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Mutagenicity	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Teratogenicity	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.
Developmental effects	: MVP Total RNA, Human HeLa S3 Cells	No known significant effects or critical hazards.
	: MVP Total RNA, Human HeLa S3 Cells, PMA-treated	No known significant effects or critical hazards.

Section 11. Toxicological information

Fertility effects : MVP Total RNA, Human HeLa S3 Cells No known significant effects or critical hazards.
MVP Total RNA, Human HeLa S3 Cells, PMA-treated No known significant effects or critical hazards.

Numerical measures of toxicity

Acute toxicity estimates

Not available.

Section 12. Ecological information

12.1 Toxicity

Not available.

12.2 Persistence and degradability

Not available.

12.3 Bioaccumulative potential

Not available.

12.4 Mobility in soil

Soil/water partition coefficient (K_{oc}) : Not available.

12.5 Other adverse effects : No known significant effects or critical hazards.

Section 13. Disposal considerations

13.1 Waste treatment methods

Disposal methods : The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non-recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible. This material and its container must be disposed of in a safe way. Empty containers or liners may retain some product residues. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

Disposal should be in accordance with applicable regional, national and local laws and regulations. Local regulations may be more stringent than regional or national requirements.

The information presented below only applies to the material as supplied. The identification based on characteristic(s) or listing may not apply if the material has been used or otherwise contaminated. It is the responsibility of the waste generator to determine the toxicity and physical properties of the material generated to determine the proper waste identification and disposal methods in compliance with applicable regulations.

Refer to Section 7: HANDLING AND STORAGE and Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION for additional handling information and protection of employees.

Section 14. Transport information

Regulatory information

DOT / IMDG / IATA : Not regulated.

Section 15. Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

U.S. Federal regulations : **United States inventory (TSCA 8b)**: All components are listed or exempted.
Clean Water Act (CWA) 311: Edetic acid

Clean Air Act Section 112 (b) Hazardous Air Pollutants (HAPs) : Not listed

Clean Air Act Section 602 Class I Substances : Not listed

Clean Air Act Section 602 Class II Substances : Not listed

DEA List I Chemicals (Precursor Chemicals) : Not listed

DEA List II Chemicals (Essential Chemicals) : Not listed

SARA 302/304

Composition/information on ingredients

No products were found.

SARA 304 RQ : Not applicable.

SARA 311/312

Classification : Not applicable.

Composition/information on ingredients

No products were found.

State regulations

Massachusetts : None of the components are listed.

New York : None of the components are listed.

New Jersey : None of the components are listed.

Pennsylvania : None of the components are listed.

California Prop. 65

No products were found.

Canada inventory : All components are listed or exempted.

International regulations

International lists : **Australia inventory (AICS)**: All components are listed or exempted.
China inventory (IECSC): All components are listed or exempted.
Japan inventory: All components are listed or exempted.
Korea inventory: All components are listed or exempted.
Malaysia Inventory (EHS Register): Not determined.
New Zealand Inventory of Chemicals (NZIoC): All components are listed or exempted.
Philippines inventory (PICCS): All components are listed or exempted.
Taiwan inventory (CSNN): All components are listed or exempted.

Section 15. Regulatory information

Chemical Weapons Convention List Schedule I Chemicals : Not listed

Chemical Weapons Convention List Schedule II Chemicals : Not listed

Chemical Weapons Convention List Schedule III Chemicals : Not listed

Section 16. Other information

History

Date of issue : 2015-09-01
Date of previous issue : No previous validation
Version : 1

 Indicates information that has changed from previously issued version.

Notice to reader

Disclaimer: The information contained in this document is based on Agilent's state of knowledge at the time of preparation. No warranty as to its accurateness, completeness or suitability for a particular purpose is expressed or implied.